An FDA panel spread misinformation about SSRI use in pregnancy, alarming doctors
Summary
An FDA panel recently questioned the safety of taking SSRIs, a type of antidepressant, during pregnancy. This has raised concerns among doctors and medical groups who argue that these medications are generally considered safe. The criticism highlights the potential for misinformation to create confusion about mental health treatment options for pregnant women.Key Facts
- An FDA panel expressed concerns about the safety of SSRIs during pregnancy.
- SSRIs, or Selective Serotonin Reuptake Inhibitors, are a type of antidepressant.
- Doctors and medical groups like the Society for Maternal-Fetal Medicine and the American College of Obstetricians and Gynecologists disagree with the panel's claims.
- Medical societies argue that untreated depression in pregnancy poses health risks.
- The FDA panel's concerns included potential risks like miscarriage and autism, but these claims were criticized as misrepresentations of evidence.
- Some cited studies did not include data on pregnant or postpartum women.
- Around 6-8% of pregnant women are prescribed SSRIs for depression and anxiety.
- The Department of Health and Human Services defended the independence and integrity of the FDA panel process.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
